Today: Today, SciClone Pharmaceuticals Inc. (SCLN) CEO Sold $715,400.00 in Stock

Today, SciClone Pharmaceuticals Inc. (SCLN) CEO Sold $715,400.00 in Stock

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) CEO Friedhelm Blobel sold 70,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $10.22, for a total value of $715,400.00. Following the completion of the sale, the chief executive officer now directly owns 102,637 shares in the company, valued at approximately $1,048,950.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Friedhelm Blobel also recently made the following trade(s): On Monday, November 14th, Friedhelm Blobel sold 30,000 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $10.27, for a total value of $308,100.00. On Thursday, October 27th, Friedhelm Blobel sold 40,000 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $9.30, for a total value of $372,000.00.

Shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) opened at 10.20 on Monday. SciClone Pharmaceuticals Inc. has a 12 month low of $7.36 and a 12 month high of $15.02. The stock has a market cap of $520.74 million, a price-to-earnings ratio of 14.57 and a beta of 1.65. The firm has a 50-day moving average price of $9.76 and a 200-day moving average price of $11.23.

Several hedge funds have recently added to or reduced their stakes in SCLN. Mason Street Advisors LLC acquired a new stake in SciClone Pharmaceuticals during the second quarter valued at approximately $127,000. GWM Advisors LLC acquired a new stake in SciClone Pharmaceuticals during the third quarter valued at approximately $104,000. Rational Advisors LLC acquired a new stake in SciClone Pharmaceuticals during the second quarter valued at approximately $140,000. Profund Advisors LLC acquired a new stake in SciClone Pharmaceuticals during the second quarter valued at approximately $141,000. Finally, Suntrust Banks Inc. raised its stake in SciClone Pharmaceuticals by 3.8% in the second quarter. Suntrust Banks Inc. now owns 11,938 shares of the specialty pharmaceutical company’s stock valued at $155,000 after buying an additional 432 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

SciClone Pharmaceuticals Company Profile

Related posts

Leave a Comment